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Abstract		
Androgenetic	alopecia	(AGA)	is	characterized	by	non-scarring	follicle	miniaturization.	Despite	the	
success	of	approved	therapies,	commonly	reported	side	effects	and	the	need	for	continual	use	has	led	
to	the	investigation	of	alternative	therapies.	The	aim	of	this	paper	is	to	critically	review	the	success	of	
off-label,	topical	monotherapies	for	treatment	of	AGA	in	men.	A	literature	search	was	conducted	to	
obtain	randomized,	controlled	and	blinded	studies	that	investigated	off-label,	topical,	monotherapies	in	
male	patients.	Hair	density,	hair	diameter	and	hair	growth	were	used	to	evaluate	treatment	success.	
Fourteen	off-label	topical	therapies	were	investigated	among	the	16	studies	that	met	inclusion	criteria.	
Nine	off-label	therapies	were	reported	to	produce	a	significantly	greater	improvement	in	hair	
restoration	parameters	(e.g.,	mean	change	from	hair	count	and	hair	diameter)	as	compared	to	placebo	
(p<0.05	for	all	treatments).	In	two	studies,	procyanidin	oligomers	exhibited	greater	efficacy	over	vehicle	
with	response	to	mean	change	in	hair	density	(hairs/cm
2
)	(ps	<	0.0001	at	week	24).	In	conclusion,	
prostaglandin	analogs	and	polyphenols,	such	as	latanoprost	and	procyanidin	oligomers,	can	improve	
hair	restoration	parameters	in	male	AGA	patients,	possibly	through	targeting	mechanisms	proposed	in	
the	etiology	of	AGA.	The	current	evidence	suggests	short	term	(24	weeks)	use	may	provide	benefit	for	
hair	loss	patients;	however,	long-term	efficacy	and	safety	data	are	required.					
	
Key	Points		
• Due	to	the	potential	side	effects	and	the	need	for	continual	use	of	approved	therapies,	there	is	a	
need	to	explore	the	efficacy	of	off-label	options.			
• Eight	off-label	topical	therapies,	including	prostaglandin	analogs	and	polyphenols,	were	found	to	
improve	hair	density,	while	one	additional	therapy	improved	hair	diameter.			
	
Keywords:	androgenetic	alopecia,	off-label	therapies,	prostaglandin	analogs,	polyphenols		
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1.0	Introduction		
	 Androgenetic	alopecia	(AGA)	is	a	common	hair	loss	disorder	characterized	by	non-scarring	
follicle	miniaturization
1
.	The	etiology	of	AGA	is	multifactorial	and	polygenetic,	with	androgens	playing	
a	pivotal	role
2,3
.	Finasteride,	an	oral	5-α	reductase	inhibitor,	and	minoxidil,	a	topical	vasodilator,	are	
FDA	and	Health	Canada	approved	for	treatment	of	AGA
4–7
.	Despite	their	success,	these	approved	
therapies	have	several	drawbacks.	Their	improvement	in	hair	restoration	parameters	tends	to	plateau	
after	a	few	years	of	continued	use.	In	addition,	these	approved	therapies	have	been	associated	with	side	
effects	such	as	skin	irritation	and	sexual	dysfunction
4–7
.	Thus,	there	is	a	need	for	new,	safe	and	effective	
treatments	for	AGA.	The	aim	of	this	paper	is	to	critically	review	the	success	of	off-label,	topical	
therapies	for	treatment	of	androgenetic	alopecia	in	men.			
2.0	Methods	of	Literature	Search		
	 A	literature	search	in	PubMed,	MEDLINE	(Ovid),	Embase	(Ovid),	and	CINAHL	was	conducted	
using	the	following	search	terms:	‘androgenetic	alopecia’,	‘male	pattern	baldness’,	‘AGA’	and	
‘randomized	controlled	trial’	(February	2018).	Randomized,	controlled	(placebo	or	vehicle)	and	blinded	
(single,	double	or	triple)	trials	that	investigated	topical	off-label	monotherapies	for	the	treatment	of	
androgenetic	alopecia	in	male	patients	were	included.	Studies	that	investigated	oral	or	combination	
therapies,	included	only	female	patients,	and/or	included	alopecia	conditions	other	than	androgenetic	
alopecia	were	excluded.	Eligible	studies	were	required	to	evaluate	treatment	success	using	hair	density	
(hair/cm
2
),	hair	diameter	(mm)	or	hair	growth	(mm/cm
2
).	Clinical	outcomes	vary	widely	among	studies;	
we	selected	a	range	of	quantitative	measurements	to	be	as	inclusive	and	objective	as	possible.		
3.0	Results	of	Literature	Search	
	 Sixteen	studies	met	inclusion	criteria	(Figure	1)
8–23
.	A	total	of	1,709	male	participants	were	
included	with	an	average	age	of	40	years.	Fourteen	off-label	topical	therapies	were	investigated:	a	
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penta-peptide	(Gly-Pro-Iie-Gly-Ser),	adenosine,	bimatoprost,	Curcuma	aeruginosa	extract,	dabao,	
fulvestrant,	a	herbal	extract,	latanoprost,	a	non-steroidal	anabolic	hormone	gel,	procyanidin	oligomers,	
pyrithione	zinc,	roxithromycin,	sodium	valproate	and	viprostol	(Tables	1-3)
8–23
.	Treatment	duration	
ranged	from	4	weeks
23
	to	52	weeks
21
	with	24	weeks	the	most	common	duration	(10/16	=	63%)
9,12,15–19,21–
23
.	Investigated	therapies	were	administered	in	a	wide	array	of	formulations	including	cream	(herbal	
extract
11
),	gel	(non-steroidal	anabolic	hormones
18
),	lotion	(adenosine,	penta-peptide,	dabao,	
roxithromycin
12-14,17
),	shampoo	(pyrithione	zinc
8
),	solution	(bimatoprost
22-23
,	latanoprost
9
,	Curcuma	
aeruginosa	extract
20
,	fulvestrant
10
,	procyanidin
16,21
,	viprostal
19
),	and	spray	(sodium	valproate
15
).		
3.1	Hair	Density		
	 Fifteen	included	studies	used	hair	density	to	evaluate	treatment	success	of	off-label	therapies	in	
AGA	patients
8–11,13,15-23
.	The	mean	change	in	hair	density	(hairs/cm
2
)	from	baseline	to	end	of	treatment	
for	off-label	therapies	ranged	from	-	4	hairs/cm
2
	to	54	hairs/cm
2
	(Table	1).	Eight	off-label	therapies	
(pyrithione	zinc	shampoo,	latanoprost,	a	herbal	extract,	adenosine,	sodium	valproate	spray,	procyanidin	
oligomers,	dabao,	and	a	non-steroidal	anabolic	hormone	solution)	had	a	significantly	higher	mean	
change	from	baseline	as	compared	to	placebo	(p<0.05	for	all	treatments)
8,9,11,13,15–18,21
.	The	highest	mean	
change	in	hair	density	(hairs/cm
2
)	after	24	weeks	of	treatment	was	found	with	latanoprost	(Figure	2)
9
.	
Two	studies	reported	procyanidin	oligomer	treatment	exhibited	greater	efficacy	over	vehicle	with	
response	to	mean	change	in	hair	density	(hairs/cm
2
)	by	end	of	24	weeks	of	treatment	(ps	<	0.001)
16,21
.				
3.2	Hair	Diameter		
	 Two	included	studies	used	changes	in	hair	diameter	to	evaluate	treatment	success	of	off-label	
therapies	in	AGA	patients	(Table	2)
8,12
.	Mean	change	in	hair	diameter	(mm)	as	compared	to	baseline	was	
significantly	higher	with	roxithromycin	as	compared	to	vehicle	after	24	weeks	of	treatment	(p	<	0.01)
12
,	
whereas,	26	weeks	of	pyrithione	zinc	treatment	was	not	significantly	different	from	placebo	treatment
8
.			
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3.3	Hair	Growth		
	 Three	studies	measured	the	impact	of	off-label	topical	therapy	on	mean	change	in	hair	growth,	
as	defined	as	mm/cm
2
	from	baseline,	compared	to	vehicle	treated	patients	(Table	3)
10,22,23
.	Bimatoprost	
treatment	once	or	twice	a	day	produced	a	mean	change	in	hair	growth	after	24	weeks	of	treatment	of	
0.76	mm/cm
2
	and	0.92	mm/cm
2
,	respectively
	22,23
.	A	significantly	lower	mean	change	in	hair	growth	was	
found	with	fulvestrant	as	compared	to	minoxidil	after	16	weeks	of	treatment	(p	<	0.001)
10
.		
4.0	Discussion	
	 In	recent	years,	many	novel	treatments	for	treating	AGA	and	other	hair	loss	have	been	
investigated.	The	objective	of	this	review	was	to	evaluate	therapeutic,	off-label	options	available	to	treat	
AGA.	The	existing	pharmaceutical	therapies	for	AGA	are	oral	finasteride	and	topical	minoxidil;	some	of	
the	off-label	treatments	discussed	in	this	review	work	via	similar	mechanisms.	Eight	off-label	therapies	
(pyrithione	zinc	shampoo,	latanoprost,	a	herbal	extract,	adenosine,	sodium	valproate	spray,	procyanidin	
oligomers,	dabao,	a	non-steroidal	anabolic	hormone	solution)	produced	significant	increases	in	hair	
density,	while	roxithromycin	significantly	increased	hair	diameter
8,9,11-13,15–18,21
.	Apart	from	
placebo/vehicle,	minoxidil	5%	was	used	as	an	active	comparator	in	three	studies,	where	it	was	
significantly	better	than	fulvestrant
10
,	numerically	similar	to	pyrithione	zinc	shampoo
8
	and	C.	aeruginosa	
extract
20
,	and	numerically	better	than	bimatoprost	formulations
22
.	Although	safety	was	not	a	focus	of	
this	review,	all	but	four	studies
8,17-19
	monitored	adverse	events.	There	were	no	adverse	events	or	
adverse	events	related	to	treatment	for	herbal	extract,	adenosine,	procyanidin	oligomers,	and	
roxithromycin.	Studies	of	bimatoprost,	latanoprost,	fulvestrant,	herbal	extract,	valproate,	and	Curcuma	
aeruginosa	reported	mild	skin-related	adverse	events	such	as	erythema,	pruritus,	urticarial,	or	
dermatitis.	Most	of	the	treatments	appear	to	be	well-tolerated	and	safe	in	the	short-term.	
6	
	
Of	the	24	week	treatments,	latanoprost,	a	prostaglandin	analog	antagonist,	was	found	to	have	
the	highest	mean	change	in	hair	density	(hairs/cm
2
)
9
.	Prostaglandin	analogs,	which	include	latanoprost,	
bimatoprost	and	viprostol,	can	stimulate	keratinocyte	and	melanocyte	activity,	enhancing	hair	growth	
and	pigmentation
24
.	Interestingly,	viprostol,	a	synthetic	prostaglandin	inhibitor,	was	not	an	effective	
treatment
19
.	This	finding	could	be	due	to	the	synthetic	nature	of	viprostol,	the	hair	loss	severity	of	
included	patients	(IIIv	to	V)	or	the	dosage	used.					
	 In	two	studies,	procyanidin	oligomers	exhibited	a	greater	efficacy	over	vehicle	by	end	of	
treatment	with	response	to	mean	change	in	hair	density	(hairs/cm2)
16,21
.	Procyanidin	oligomers,	and	
other	polyphenols,	most	likely	promote	hair	growth	via	nitric	oxide,	a	gas	produced	in	the	lining	of	veins	
which	promotes	vasodilation	and	reduces	cholesterol	build-up.	Polyphenols	have	also	been	shown	to	
inhibit	5α-reductase	activity	which	has	been	theorized	to	play	a	role	in	the	pathogenesis	of	AGA
25
.		
	 Regardless	of	these	promising	effects,	more	clinical	trials	need	to	be	conducted	before	the	use	
of	these	off-label	treatments	is	sanctioned.	Of	particular	note	is	that	the	current	evidence	for	off-label	
treatments	is	from	clinical	studies	that	are	short	in	duration,	with	24	weeks	the	most	common.	Long-
term	efficacy	and	safety	data	are	not	available	and	we	are	thus	unable	to	draw	comparisons	with	
approved	therapies.	While	improvement	can	plateau	over	time	with	finasteride	and	minoxidil,	the	long-
term	efficacy	of	off-label	treatments	is	unknown.	The	patients	in	the	included	studies	were	
predominantly	male	and	differences	in	treatment	efficacy	between	males	and	females	should	be	kept	in	
mind.	Therapies	with	multi-factorial	capabilities	may	be	more	appropriate	for	treating	female	pattern	
hair	loss,	whereas,	male	pattern	hair	loss	patients	benefit	more	from	a	direct	anagen	effect
2
.			
Additionally,	an	important	limitation	when	evaluating	efficacy	of	hair	loss	treatments	is	the	
variety	of	outcome	measures	used	to	measure	successful	hair	growth;	there	is	no	accepted	industry	
standard.		Assessment	of	global	photographs	by	an	expert,	hair	counts	using	phototrichogram,	and	
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manual	hair	counts	using	clippings	or	hair	density	in	a	target	area	were	all	reported	in	studies.	Global	
assessments	based	on	photographs,	for	example,	can	offer	useful	insight,	but	they	are	not	the	same	as	
blinded	quantitative	measurement.	Hair	count	can	be	converted	into	hair	density	when	a	target	area	is	
provided	by	the	authors,	but	not	all	authors	disclosed	this	information.	This	should	be	a	point	of	
consideration	in	the	development	of	new	trials	as	a	consistent	quantitative	outcome	measure	can	aid	in	
comparing	different	treatments.	Patient-centred	outcomes	such	as	satisfaction	are	also	important.	
While	the	reported	data	(Tables	1-3)	certainly	show	an	increase	in	hair	parameters,	increases	may	not	
be	noticeable	or	satisfactory	for	patients	to	justify	treatment	or,	patients	may	express	satisfaction	
despite	little	to	no	clinical	improvement.	Even	if	patients	believe	a	treatment	is	beneficial,	a	case	can	be	
made	that	clinicians	should	not	encourage	use	of	treatments	that	do	not	objectively	improve	hair	loss.	
5.0	Conclusion		
	 Preliminary	evidence	suggests	that,	in	the	short-term,	eight	off-label	therapies	such	as	
prostaglandin	analogs	and	polyphenols	can	significantly	improve	hair	density
8,9,11,13,15–18,21
.	Further	study	
of	hair	loss	patients	enrolled	in	randomized,	controlled	and	blinded	studies	is	needed	to	expand	on	the	
efficacy	and	safety	data	that	has	been	collected	to	date.			In	the	meantime,	clinicians	may	wish	to	use	
off-label	therapies	as	they	may	provide	benefit	to	patients.	Hair	loss	needs	should	be	addressed	
individually	as	both	off-label	and	approved	treatment	that	works	for	one	person	may	not	work	for	
another.			
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Figure	Captions:	
Figure	1:	Study	Selection	Process	
Figure	2:	Mean	Change	in	Hair	Density	(hairs/cm
2
)	after	24	weeks	of	Off-Label	Topical	Therapy
8,9,13–22
.	
Bimatoprost	A,	B,	and	C:	Details	on	these	treatment	groups	(e.g.,	percentage	of	bimatoprost)	not	yet	
released	on	clinicaltrials.gov;	Dabao:	50%	ethanol,	42%	water,	8%	Chinese	herbal	extracts	(saffron	
flowers,	mulberry	leaves,	stemona	root,	fruits	of	the	pepper	plant,	sesame	leaves,	the	skin	of	the	fruit	of	
Sichuan	pepper,	ginger	root,	Chinese	angelica	root,	bark	of	the	Pseudolarix,	fruits	of	the	hawthorn);	
Latanoprost:	50%	ethanol,	20%	propylene	glycol	water;	Non-steroidal	anabolic	hormones	(NSAH):	
CMM,	made	of	insulin,	thyroxin	and	growth	hormone	gelled	in	1.5%	hydroxyethyl	cellulose;	Procyanidin	
B-2:	70%	ethanol,	10%	1,3-butylene	glycol,	0.5%	N-acetylglutamine-isostearyl	ester,	
0.25%polyoxyethylene	glyceryl	monopyroglutamate	monoisosterate,	0.1%	dl-α-tocopherol,	0.05%	d-
biotin,	0.1%	ascorbyl	palmitate,	0.001%	β-carotene,	0.1%	sodium	citrate	and	17.899%	purified	water;	
Procyanidin	Mix:	7.3%	procyanidin	B-1,	26.2%	procyanidin	B-2,	7.7%	procyanidin	C-1,	40%	other	
oligomeric	procyanidins,	70%	ethanol,	3%	1,3-butylene	glycol,	0.15%	N-acetylglutamine	isostearyl	ester,	
0.067%	citrate-sodium	citrate	buffer,	0.05%	sodium	bisulfite,	purified	water;	Sodium	Valproate:	8.3%	
sodium	valproate	using	a	27%	ethanol	solution	as	the	vehicle.	
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Table	1:	Impact	of	Off-Label	Topical	Therapy	on	Hair	Density	(hairs/cm
2
)	by	End	of	Treatment	
Study	 Characteristics	 Treatment	Details	 Mean	Change	From	Baseline	
Berger	et	al.	2003
8
	
N:	200	
Age:	40	
Severity:	IIIv	to	IV	
Duration:	26	wks	
Placebo	Shampoo	(1x	day)	 -1	hairs/cm
2
	
Pyrithione	Zinc	Shampoo	(1%,	1x	day)	 6	hairs/cm
2
*	
Pyrithione	Zinc	Shampoo	(1%,	1x	day)	+	Minoxidil	(5%,	2x	day)	 6	hairs/cm
2
*	
Minoxidil	(5%,	2x	day)	+	Placebo	Shampoo	(1x	day)	 12	hairs/cm
2
*	
Blume-Peytavi	et	al.	2012
9
	
N:	16	
Age:	(23-35)	
Severity:	II	to	III	
Duration:	24	wks	
Placebo	(50	µL/day)	 8	hairs/cm
2
	
Latanoprost	(0.1%,	50	µL/day)	 51	hairs/cm
2
*	
Gassmueller	et	al.	2008
10
	
N:	102	
Age:	38	
Severity:	III	to	Va	
Duration:	16	wks	
Vehicle	(2x	day)	 8	hairs/cm
2
	
Fulvestrant	(70	mg/mL,	42	mg/day)	 8	hairs/cm
2
	
Minoxidil		(20	mg/mL,	12	mg/day)	 25	hairs/cm
2
**	
Greenberg	&	Katz	1996
11
	
N:	24	
Age:	43	
Severity:	III	to	IV	
Duration:	40	wks	
Vehicle	(1x	day)	 6	hairs/cm
2
	
Herbal	Extract	(1x	day)	 54	hairs/cm
2
*	
Iwabuchi	et	al.	2016a
13
	
N:	38	
Age:	42	
Duration:	24	wks	
Vehicle		 -10	hairs/cm
2
	
Adenosine	(0.75%)		 12	hairs/cm
2
*	
Jo	et	al.	2014
15
	
N:	40	
Age:	38	
Severity:	IIIv	to	V	
Duration:	24	wks	
Vehicle	(0.8	mL/dose,	2x	day)		 -1	hairs/cm
2a
	
Sodium	Valproate	Spray	(0.8	mL/dose,	2x	day)	 23	hairs/cm
2a
*	
Kamimura	et	al.	2000
16
	
N:	30	
Age:	47	
Duration:	24	wks	
Placebo	(1%,	1.8	mL	2x	day)	 4	hairs/cm
2
	
Procyanidin	B-2	(1%,	1.8	mL	2x	day)	 28	hairs/cm
2
*	
Kessels	et	al.	1991
17
	
N:	396	
Duration:	24	wks	
Placebo	(1.7	mL,	2x	day)	 22	hairs/cm
2
	
Dabao	(1.7	mL,	2x	day)	 27	hairs/cm
2
*	
Lindenbaum	et	al.	2003
18
	
N:	56	
Age:	28	
Severity:	II	to	IV	
Duration:	24	wks	
Placebo	(1-3	mL/day)	 16	hairs/cm
2
	
Non-Steroidal	Anabolic	Hormones	(1-3	mL/day)	 30	hairs/cm
2
*	
NCT01325337
22
	
N:	307	
Duration:	24	wks	
Vehicle	(1x	day)	 4	hairs/cm
2b
	
Bimatoprost	Formulation	B	(1x	day)	 6	hairs/cm
2b
	
Bimatoprost	Formulation	C	(1x	day)	 6	hairs/cm
2b
	
Bimatoprost	Formulation	A	(1x	day)	 13	hairs/cm
2b
	
Minoxidil	(5%,	1x	day)		 22	hairs/cm
2b
	
NCT01904721
23
	
N:	244	
Duration:	7-24	wks	
Bimatoprost	Solution	1	(2x	day)	 13	hairs/cm
2b
	
Bimatoprost	Solution	2	(2x	day)	 9	hairs/cm
2b
	
Vehicle	(2x	day)	 6	hairs/cm
2b
	
Olsen	&	DeLong	et	al.	
1990
19
	
N:	72	
Age:	38	
Severity:	IIIv	to	V	
Duration:	24	wks	
Vehicle	(0.3	mL/dose,	2x	day)	 -8	hairs/cm
2
	
Viprostol	(120	µg,	0.3	mL/dose,	2x	day)	 -4	hairs/cm
2
	
Placebo	(0.3	mL/dose,	2x	day)	 -3	hairs/cm
2
	
Pumthong	et	al.	2012
20
	
N:	89	
Age:	39	
Severity:	II-VII	
Duration:	24	wks	
Vehicle	(2x	day)	 20	hairs/cm
2
	
Curcuma	aeruginosa	extract	(5%,	2x	day)	 31	hairs/cm
2
	
Minoxidil	(5%,	2x	day)	 31	hairs/cm
2
	
Minoxidil	(5%,	2x	day)	+	Curcuma	aeruginosa	extract	(5%,	2x	
day)	
33	hairs/cm
2
	
Takahashi	et	al.	2005
21
	
N:	49	
Age:	(27-58)	
Duration:	24-52	wks	
Vehicle	(2	mL	2x	day)	 -8	hairs/cm
2
	
Procyanidin	(0.7%,	2	mL	2x	day)	 6	hairs/cm
2
*	
*p<0.05	as	compared	to	placebo	/	vehicle;	**p<0.05	as	compared	to	comparator;	a:	median	change;	b:	terminal	hairs	were	used;	Age	(years):	Mean	(range);	Severity:	
Based	on	Hamilton-Norwood	Scale	and	eligibility	criteria;	Wks:	weeks;	Latanoprost:	50%	ethanol,	20%	propylene	glycol	water;	Herbal	extract:	7.5%	extract	of	fennel,	
13	
	
polygonum,	mentha,	chamomile,	thuja	and	hibiscus	in	a	water-based	cream;	Sodium	Valproate	Spray:	8.3%	sodium	valproate	using	a	27%	ethanol	solution	as	the	vehicle;	
Procyanidin	B-2:	70%	ethanol,	10%	1,3-butylene	glycol,	0.5%	N-acetylglutamine-isostearyl	ester,	0.25%polyoxyethylene	glyceryl	monopyroglutamate	monoisosterate,	
0.1%	dl-α-tocopherol,	0.05%	d-biotin,	0.1%	ascorbyl	palmitate,	0.001%	β-carotene,	0.1%	sodium	citrate	and	17.899%	purified	water;	Procyanidin:	7.3%	procyanidin	B-1,	
26.2%	procyanidin	B-2,	7.7%	procyanidin	C-1,	40%	other	oligomeric	procyanidins,	70%	ethanol,	3%	1,3-butylene	glycol,	0.15%	N-acetylglutamine	isostearyl	ester,	0.067%	
citrate-sodium	citrate	buffer,	0.05%	sodium	bisulfite,	purified	water;	Dabao:	50%	ethanol,	42%	water,	8%	Chinese	herbal	extracts	(saffron	flowers,	mulberry	leaves,	
stemona	root,	fruits	of	the	pepper	plant,	sesame	leaves,	the	skin	of	the	fruit	of	Sichuan	pepper,	ginger	root,	Chinese	angelica	root,	bark	of	the	Pseudolarix,	fruits	of	the	
hawthorn);	Non-steroidal	anabolic	hormones:	CMM,	made	of	insulin,	thyroxin	and	growth	hormone	gelled	in	1.5%	hydroxyethyl	cellulose;	Bimatoprost	A,	B,	C,	1	and	2:	
Details	on	these	treatment	groups	(e.g.,	percentage	of	bimatoprost)	not	yet	released	on	clinicaltrials.gov	
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Table	2:	Impact	of	Off-Label	Topical	Therapy	on	Hair	Diameter	(mm)	by	End	of	Treatment
8,14
	
Study	 Characteristics	 Treatment	Details	 Mean	Change	from	Baseline		
Berger	et	al.	2003
8
	
N:	200	
Age:	40	
Severity:	IIIv	to	IV	
Duration:	26	wks	
Placebo	Shampoo	(1x	day)	 -0.04	mm	
Pyrithione	Zinc	Shampoo	(1%,	1x	day)	 -0.04	mm		
Pyrithione	Zinc	Shampoo	(1%,	1x	day)	+	Minoxidil	(5%,	2x	day)	 -0.01	mm		
Minoxidil	(5%,	2x	day)	+	Placebo	Shampoo	(1x	day)	 -0.01	mm		
Ito	et	al.	2009
12
	
N:	24	
Age:	48	
Severity:	II	to	IIIV	
Duration:	24	wks	
Vehicle	 0.0004	mm	
Roxithromycin	 0.309	mm*		
*p<0.01	as	compared	to	baseline;	Age	(years):	Mean	(range);	Severity:	Based	on	Hamilton-Norwood	Scale	and	eligibility	criteria;	Wks:	weeks;	Roxithromycin:	0.5%	
Roxithromycin,	65%	ethyl	alcohol,	5%	propylene	glycol,	39.5%	distilled	water	
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Table	3:	Impact	of	Off-Label	Topical	Therapy	on	Hair	Growth	(mm/cm
2
)	by	End	of	Treatment
10,24,25	
Study	 Characteristics	 Treatment	Details	 Mean	Change	from	Baseline		
Gassmueller	et	al.	2008
10
	
N:	102	
Age:	38	
Severity:	III	to	Va	
Duration:	16	wks	
Vehicle	(2x	day)	 0.7	mm/cm
2
	
Fulvestrant	(70	mg/mL,	42	mg/day)	 0.84	mm/cm
2
	
Minoxidil		(20	mg/mL,	12	mg/day)	 2.9	mm/cm
2
*,^
	
NCT01325337
22	 N:	307	
Duration:	24	wks	
Bimatoprost	Formulation	C	(1x	day)	 0.12	mm/cm
2
	
Vehicle	(1x	day)	 0.13	mm/cm
2
	
Bimatoprost	Formulation	B	(1x	day)	 0.25	mm/cm
2
	
Bimatoprost	Formulation	A	(1x	day)	 0.76	mm/cm
2
	
Minoxidil	(5%,	1x	day)		 1.29	mm/cm
2
	
NCT01904721
23	 N:	244	
Duration:	7-24	wks	
Vehicle	(2x	day)	 0.05	mm/cm
2
	
Bimatoprost	Solution	2	(2x	day)	 0.67	mm/cm
2
	
Bimatoprost	Solution	1	(2x	day)	 0.92	mm/cm
2
	
*p<0.05	as	compared	to	placebo	/	vehicle;	^p<0.05	as	compared	to	investigated	off-label	topical	therapy;	Age	(years):	Mean;	Severity:	Based	on	Hamilton-Norwood	Scale	
and	eligibility	criteria;	Wks:	weeks;	Bimatoprost	A,	B,	C,	solution	1	and	solution	2:	Details	on	these	treatment	groups	(e.g.,	percentage	of	bimatoprost)	not	yet	released	on	
clinicaltrials.gov		
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Figure	1.	
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Figure	2	
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